| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13,144 |
12,606 |
$963K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,581 |
7,389 |
$824K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,069 |
4,051 |
$458K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,517 |
2,505 |
$419K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
864 |
864 |
$232K |
| 95816 |
|
690 |
687 |
$227K |
| 95886 |
|
1,108 |
1,003 |
$167K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,924 |
783 |
$166K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
523 |
523 |
$132K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
365 |
355 |
$100K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,726 |
1,006 |
$88K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
492 |
481 |
$69K |
| 95912 |
|
288 |
287 |
$68K |
| 72141 |
|
273 |
272 |
$66K |
| 00630 |
|
298 |
277 |
$64K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,560 |
934 |
$56K |
| 95911 |
|
249 |
245 |
$52K |
| 20611 |
|
428 |
397 |
$41K |
| 95822 |
|
101 |
101 |
$31K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
644 |
611 |
$29K |
| 73560 |
|
785 |
674 |
$26K |
| 73610 |
|
852 |
778 |
$25K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
197 |
194 |
$22K |
| 72275 |
|
242 |
218 |
$22K |
| 73630 |
|
762 |
685 |
$22K |
| 95819 |
|
65 |
65 |
$20K |
| 97014 |
|
1,105 |
485 |
$16K |
| 73110 |
|
475 |
404 |
$16K |
| 97161 |
|
200 |
192 |
$16K |
| 96112 |
|
117 |
115 |
$15K |
| 20610 |
|
189 |
171 |
$12K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
111 |
111 |
$9K |
| 80305 |
|
1,100 |
1,081 |
$9K |
| T1013 |
Sign language or oral interpretive services, per 15 minutes |
502 |
500 |
$8K |
| 73221 |
|
26 |
26 |
$7K |
| 93040 |
|
611 |
554 |
$7K |
| 73030 |
|
240 |
219 |
$7K |
| 95953 |
|
25 |
13 |
$5K |
| 73562 |
|
150 |
120 |
$5K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
447 |
399 |
$5K |
| 73140 |
|
158 |
137 |
$5K |
| 83789 |
|
448 |
442 |
$4K |
| 29540 |
|
198 |
194 |
$4K |
| 80363 |
|
842 |
821 |
$2K |
| 97165 |
|
32 |
31 |
$2K |
| 80323 |
|
829 |
819 |
$2K |
| 80349 |
|
797 |
787 |
$2K |
| 80346 |
|
726 |
703 |
$2K |
| 80324 |
|
730 |
706 |
$2K |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
112 |
105 |
$2K |
| 83992 |
|
643 |
635 |
$2K |
| 80358 |
|
806 |
796 |
$2K |
| 96138 |
|
132 |
131 |
$1K |
| 96119 |
|
13 |
13 |
$974.99 |
| 80345 |
|
659 |
650 |
$850.57 |
| 97164 |
|
15 |
14 |
$846.34 |
| 80353 |
|
660 |
651 |
$818.46 |
| 73130 |
|
29 |
25 |
$814.72 |
| 72100 |
|
14 |
13 |
$421.62 |
| 80355 |
|
606 |
598 |
$384.05 |
| 96118 |
|
15 |
15 |
$287.37 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
441 |
405 |
$233.39 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
669 |
616 |
$176.70 |
| 97010 |
|
463 |
190 |
$175.84 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
39 |
38 |
$157.50 |
| 96102 |
|
43 |
43 |
$154.45 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
232 |
213 |
$105.11 |
| 93225 |
|
13 |
12 |
$103.24 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
648 |
642 |
$100.09 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
20 |
20 |
$86.83 |
| 82542 |
|
155 |
152 |
$72.27 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
20 |
12 |
$58.80 |
| 84311 |
|
157 |
154 |
$25.89 |
| 82570 |
|
157 |
154 |
$19.17 |
| 83986 |
|
157 |
154 |
$13.26 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
446 |
435 |
$1.40 |